The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era

E-ISSN： 1365-2141|175|1|102-114

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.175, Iss.1, 2016-10, pp. : 102-114

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Retreatment with rituximab offers a similar survival benefit as maintenance therapy in patients with low tumor burden follicular lymphoma

CA: A CANCER JOURNAL FOR CLINICIANS, Vol. 65, Iss. 1, 2015-01 ,pp. : 1-2

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced‐stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 4, 2015-05 ,pp. : 544-551

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prolonged Remission in a Patient with Relapsed Follicular Lymphoma after a Single Course of Rituximab

Oncology Research and Treatment, Vol. 29, Iss. 3, 2006-03 ,pp. : 90-92

Karger

Access to resources Recommend Favorite

Immunochemotherapy with Rituximab, Vincristine and 5-Day Cyclophosphamide for Heavily Pretreated Follicular Lymphoma

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 146-153

Karger

Access to resources Recommend Favorite

Low‐dose chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab in follicular lymphoma

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 277-278

John Wiley & Sons Inc

Access to resources Recommend Favorite